Search
News
Study Shows Walking an Hour a Day Achieves Greatest Longevity Benefit
Researchers from the National Cancer Institute, the American Cancer Society, and others have found that getting 3 to 5 times the amount of recommended leisure-time physical activity results in the greatest benefit in terms of a longer life. The study was published online April 6, 2015 in JAMA Internal Medicine. One way to achieve this benefit is by walking an hour a day.
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy
Hormonal therapies, such as aromatase inhibitors (AI) and tamoxifen, significantly increase disease-free survival and reduce the risk of recurrence in breast cancer patients [1–3]. However, patients and survivors often experience unpleasant side effects from these therapies including musculoskeletal symptoms (joint pain and stiffness), bone loss, and menopausal symptoms [4]. Phase III trials, using the National […]
Annual Report to the Nation: Cancer Death Rates Still Dropping
By Stacy Simon The death rate from cancer in the United States is continuing the decline that began in the early 1990s, according to the latest Annual Report to the Nation on the Status of Cancer. It shows the rate of death from cancer in the United States is going down among both men and women, […]
A phase I–II evaluation of veliparib (NSC#737664), topotecan, and filgrastim or pegfilgrastim
Poly(ADP-ribose) polymerase (PARP) acts as a constitutively-expressed nuclear tankyrase enzyme primarily involved in mammalian base excision DNA repair [1–3]. PARP rapidly catalyzes the new synthesis of ADP-ribose branching polymers from its substrate nicotinamide adenine dinucleotide, creating negatively-charged, branching scaffolds upon which other nuclear proteins such as DNA polβ, X-ray repair cross-complementing factor 1 (XRCC1), and DNA ligase III co-localize to DNA [4,5]. As such, PARP functions as a key regulator of both base excision DNA damage repair and DNA duplication [5–10].
Phase III double-blind, placebo-controlled study of gabapentin
BACKGROUND: Despite targeted antiemetics, data support an unmet need related to the management of delayed nausea and vomiting (NV). Promising pilot data informed this phase III trial evaluating gabapentin for delayed NV from highly emetogenic chemotherapy (HEC). METHODS: Participants were randomized to receive prophylactic treatment with 20 mg of dexamethasone and a 5HT3 receptor antagonist […]
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin
BACKGROUND: Despite targeted antiemetics, data support an unmet need related to the management of delayed nausea and vomit-ing (NV). Promising pilot data informed this phase III trial evaluating gabapentin for delayed NV from highly emetogenic chemother-apy (HEC). METHODS: Participants were randomized to receive prophylactic treatment with 20 mg of dexamethasone and a 5HT3 receptor antagonist […]
Randomized phase II adjuvant factorial study of dose-dense temozolomide
Despite optimal therapy with radiation and concurrent and ad-juvant temozolomide (TMZ),1 survival is poor for most patients with glioblastoma (GBM), and effective second-line therapies are scarce.2,3 Even in the context of clinical trials, 3-year survival is only 16%, and 5-year survival is 10%.4 There is an urgent need for more effective first-line therapies. The implementation […]
Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan
Although the incidence of small-cell lung cancer (SCLC) is decreasing in the United States, perhaps because of the changing smoking patterns, there have been no significant changes in its outcome in more than 3 decades.1 The majority of patients with SCLC present with extensive stage disease and are treated palliatively with platinum-based chemother-apy. Although response […]
Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer
Background. Although preoperative chemotherapy (cisplatin-etoposide) and radiotherapy, followed by sur-gical resection, is considered a standard of care for superior sulcus cancers, treatment is rigorous and relapse limits long-term survival. The Southwest Oncology Group-Intergroup Trial S0220 was designed to incorporate an active systemic agent, docetaxel, as consolidation therapy. Methods. Patients with histologically proven and radio-logically defined […]
